Dyadic International, Inc. vs. Moderna, Inc. Common Stock
Moderna, Inc. Common Stock (MRNA) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| DYAI | MRNA | |
|---|---|---|
| Market Cap | $16.67 million | $79.40 billion |
| Revenue (TTM) | — | $2.23 billion |
| Net Income (TTM) | — | $-3,151,000,000 |
MRNA leads on 1 of 1 size & scale factors.
Valuation
| DYAI | MRNA | |
|---|---|---|
| Price / Book | — | 11.74 |
| Price / Sales | — | 35.64 |
DYAI and MRNA split the valuation factors evenly.
Profitability
| DYAI | MRNA | |
|---|---|---|
| Net Margin | — | -141.43% |
| Return on Equity | — | -46.61% |
DYAI and MRNA split the profitability factors evenly.
Risk & Sentiment
| DYAI | MRNA | |
|---|---|---|
| Short Interest | 0.01% | 0.01% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: DYAI overview, DYAI financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.
